More than 91% of U.S. Adults Say Cannabis Should be Legal
Mon November 25, 2019
Houston, Texas--(Newsfile Corp. - November 25, 2019) - MarijuanaStox announces publication of an article that discusses The Yield Growth Corporation (CSE: BOSS) (OTC: BOSQF). The company has been aggressively addressing demand for health, wellness, and beauty products infused with premium-cannabis and hemp-based products on an international scale with subsidiary, Urban Juve.
Cannabis stocks haven't had a great 2019. However, that may change in 2020.
Support for the legalization of cannabis has been explosive.
According to a new Pew Research Center survey, two-thirds of Americans say cannabis should be legalized. Better, only 32% of U.S. adults oppose legalization nowadays, as compared to 52% in 2010. "An overwhelming majority of U.S. adults (91%) say marijuana should be legal either for medical and recreational use (59%) or that it should be legal just for medical use (32%)."
Even better, the House Judiciary Committee just advanced the Marijuana Opportunity Reinvestment and Expungement Act (More Act).
"Our marijuana laws disproportionately harm individuals and communities of color, leading to convictions that damage job prospects, access to housing, and the ability to vote," Committee Chairman Jerrold Nadler said, as quoted by MarketWatch. "Recognizing this, many states have legalized marijuana. It's now time for us to remove the criminal prohibitions against marijuana at the federal level," he added.
Should it now pass other committee votes in the House, the MORE Act will make its way to the U.S. Senate. That's just one substantial catalyst for cannabis investors.
Plus, as the race for the White House heats up, candidates are talking about cannabis. President Donald Trump for example has said he would support bipartisan efforts in Congress (CACOX) to ease the federal ban on marijuana.
In short, there are plenty of catalysts for cannabis growth moving forward.
The Yield Growth Corporation is One of the Major Beneficiaries
It's been quite a year for The Yield Growth Corporation.
In its third quarter of 2019, revenue increased 61% to $1.9 million in Q3 2019 compared to $1.2 million in Q2 2019, and increased by 355% compared to $0.4 million in Q3 2018. Net losses decreased by 55% to $1.9 million in Q3 2019 compared to $4.1 million in Q2 2019, and decreased by 50% compared to $3.7 million in Q3 2018.
The company also made considerable progress in building its assets, positioning itself for future growth. Total assets increased by 149% to $6.5 million from $2.6 million at 2018 year-end. Net assets increased by 250% to $4.7 million from $1.3 million at 2018 year-end. Working capital increased by 91% to $3.4 million from $1.8 million at 2018 year-end.
While CBD is a big part of the company's international growth, so are mushrooms.
In fact, Yield Growth just entered into a definitive agreement with Eurolife Brands (EURPF) for the exclusive distribution of Yield Growth's line of mushroom infused coffee mixes being developed through subsidiary Flourish Mushroom Labs Inc. The distribution agreement grants Eurolife Brands exclusive distribution rights in Germany, the United Kingdom and Switzerland for the mushroom coffee line being developed by Yield Growth subsidiary Flourish Mushroom Labs.
"We are excited about the potential for therapeutic use of legal edible mushrooms and intend to launch our coffee products in Canada and the U.S. in 2020," says Penny White, Yield Growth CEO. "We are also researching the legality of developing products or conducting trials on products that contain psilocin or psilocybin from magic mushrooms for potential medical use."
For more information, visit the company's website at https://yieldgrowth.com
https://seekingalpha.com/pr/17710175-91-perce...abis-legal
Mon November 25, 2019
Houston, Texas--(Newsfile Corp. - November 25, 2019) - MarijuanaStox announces publication of an article that discusses The Yield Growth Corporation (CSE: BOSS) (OTC: BOSQF). The company has been aggressively addressing demand for health, wellness, and beauty products infused with premium-cannabis and hemp-based products on an international scale with subsidiary, Urban Juve.
Cannabis stocks haven't had a great 2019. However, that may change in 2020.
Support for the legalization of cannabis has been explosive.
According to a new Pew Research Center survey, two-thirds of Americans say cannabis should be legalized. Better, only 32% of U.S. adults oppose legalization nowadays, as compared to 52% in 2010. "An overwhelming majority of U.S. adults (91%) say marijuana should be legal either for medical and recreational use (59%) or that it should be legal just for medical use (32%)."
Even better, the House Judiciary Committee just advanced the Marijuana Opportunity Reinvestment and Expungement Act (More Act).
"Our marijuana laws disproportionately harm individuals and communities of color, leading to convictions that damage job prospects, access to housing, and the ability to vote," Committee Chairman Jerrold Nadler said, as quoted by MarketWatch. "Recognizing this, many states have legalized marijuana. It's now time for us to remove the criminal prohibitions against marijuana at the federal level," he added.
Should it now pass other committee votes in the House, the MORE Act will make its way to the U.S. Senate. That's just one substantial catalyst for cannabis investors.
Plus, as the race for the White House heats up, candidates are talking about cannabis. President Donald Trump for example has said he would support bipartisan efforts in Congress (CACOX) to ease the federal ban on marijuana.
In short, there are plenty of catalysts for cannabis growth moving forward.
The Yield Growth Corporation is One of the Major Beneficiaries
It's been quite a year for The Yield Growth Corporation.
In its third quarter of 2019, revenue increased 61% to $1.9 million in Q3 2019 compared to $1.2 million in Q2 2019, and increased by 355% compared to $0.4 million in Q3 2018. Net losses decreased by 55% to $1.9 million in Q3 2019 compared to $4.1 million in Q2 2019, and decreased by 50% compared to $3.7 million in Q3 2018.
The company also made considerable progress in building its assets, positioning itself for future growth. Total assets increased by 149% to $6.5 million from $2.6 million at 2018 year-end. Net assets increased by 250% to $4.7 million from $1.3 million at 2018 year-end. Working capital increased by 91% to $3.4 million from $1.8 million at 2018 year-end.
While CBD is a big part of the company's international growth, so are mushrooms.
In fact, Yield Growth just entered into a definitive agreement with Eurolife Brands (EURPF) for the exclusive distribution of Yield Growth's line of mushroom infused coffee mixes being developed through subsidiary Flourish Mushroom Labs Inc. The distribution agreement grants Eurolife Brands exclusive distribution rights in Germany, the United Kingdom and Switzerland for the mushroom coffee line being developed by Yield Growth subsidiary Flourish Mushroom Labs.
"We are excited about the potential for therapeutic use of legal edible mushrooms and intend to launch our coffee products in Canada and the U.S. in 2020," says Penny White, Yield Growth CEO. "We are also researching the legality of developing products or conducting trials on products that contain psilocin or psilocybin from magic mushrooms for potential medical use."
For more information, visit the company's website at https://yieldgrowth.com
https://seekingalpha.com/pr/17710175-91-perce...abis-legal
